Cargando…

Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder

SUMMARY: A 53-year-old man who used growth hormone (GH), anabolic steroids and testosterone (T) for over 20 years presented with severe constipation and hypercalcaemia. He had benign prostatic hyperplasia and renal stones but no significant family history. Investigations showed – (1) corrected calci...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravindran, Ravikumar, Witczak, Justyna, Bahl, Suhani, Premawardhana, Lakdasa D K E, Adlan, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354728/
https://www.ncbi.nlm.nih.gov/pubmed/32698126
http://dx.doi.org/10.1530/EDM-20-0032
_version_ 1783558150674186240
author Ravindran, Ravikumar
Witczak, Justyna
Bahl, Suhani
Premawardhana, Lakdasa D K E
Adlan, Mohamed
author_facet Ravindran, Ravikumar
Witczak, Justyna
Bahl, Suhani
Premawardhana, Lakdasa D K E
Adlan, Mohamed
author_sort Ravindran, Ravikumar
collection PubMed
description SUMMARY: A 53-year-old man who used growth hormone (GH), anabolic steroids and testosterone (T) for over 20 years presented with severe constipation and hypercalcaemia. He had benign prostatic hyperplasia and renal stones but no significant family history. Investigations showed – (1) corrected calcium (reference range) 3.66 mmol/L (2.2–2.6), phosphate 1.39 mmol/L (0.80–1.50), and PTH 2 pmol/L (1.6–7.2); (2) urea 21.9 mmol/L (2.5–7.8), creatinine 319 mmol/L (58–110), eGFR 18 mL/min (>90), and urine analysis (protein 4+, glucose 4+, red cells 2+); (3) creatine kinase 7952 U/L (40–320), positive anti Jo-1, and Ro-52 antibodies; (4) vitamin D 46 nmol/L (30–50), vitamin D3 29 pmol/L (55–139), vitamin A 4.65 mmol/L (1.10–2.60), and normal protein electrophoresis; (5) normal CT thorax, abdomen and pelvis and MRI of muscles showed ‘inflammation’, myositis and calcification; (6) biopsy of thigh muscles showed active myositis, chronic myopathic changes and mineral deposition and of the kidneys showed positive CD3 and CD45, focal segmental glomerulosclerosis and hypercalcaemic tubular changes; and (7) echocardiography showed left ventricular hypertrophy (likely medications and myositis contributing), aortic stenosis and an ejection fraction of 44%, and MRI confirmed these with possible right coronary artery disease. Hypercalcaemia was possibly multifactorial – (1) calcium release following myositis, rhabdomyolysis and acute kidney injury; (2) possible primary hyperparathyroidism (a low but detectable PTH); and (3) hypervitaminosis A. He was hydrated and given pamidronate, mycophenolate and prednisolone. Following initial biochemical and clinical improvement, he had multiple subsequent admissions for hypercalcaemia and renal deterioration. He continued taking GH and T despite counselling but died suddenly of a myocardial infarction. LEARNING POINTS: The differential diagnosis of hypercalcaemia is sometimes a challenge. Diagnosis may require multidisciplinary expertise and multiple and invasive investigations. There may be several disparate causes for hypercalcaemia, although one usually predominates. Maintaining ‘body image’ even with the use of harmful drugs may be an overpowering emotion despite counselling about their dangers.
format Online
Article
Text
id pubmed-7354728
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-73547282020-07-15 Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder Ravindran, Ravikumar Witczak, Justyna Bahl, Suhani Premawardhana, Lakdasa D K E Adlan, Mohamed Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: A 53-year-old man who used growth hormone (GH), anabolic steroids and testosterone (T) for over 20 years presented with severe constipation and hypercalcaemia. He had benign prostatic hyperplasia and renal stones but no significant family history. Investigations showed – (1) corrected calcium (reference range) 3.66 mmol/L (2.2–2.6), phosphate 1.39 mmol/L (0.80–1.50), and PTH 2 pmol/L (1.6–7.2); (2) urea 21.9 mmol/L (2.5–7.8), creatinine 319 mmol/L (58–110), eGFR 18 mL/min (>90), and urine analysis (protein 4+, glucose 4+, red cells 2+); (3) creatine kinase 7952 U/L (40–320), positive anti Jo-1, and Ro-52 antibodies; (4) vitamin D 46 nmol/L (30–50), vitamin D3 29 pmol/L (55–139), vitamin A 4.65 mmol/L (1.10–2.60), and normal protein electrophoresis; (5) normal CT thorax, abdomen and pelvis and MRI of muscles showed ‘inflammation’, myositis and calcification; (6) biopsy of thigh muscles showed active myositis, chronic myopathic changes and mineral deposition and of the kidneys showed positive CD3 and CD45, focal segmental glomerulosclerosis and hypercalcaemic tubular changes; and (7) echocardiography showed left ventricular hypertrophy (likely medications and myositis contributing), aortic stenosis and an ejection fraction of 44%, and MRI confirmed these with possible right coronary artery disease. Hypercalcaemia was possibly multifactorial – (1) calcium release following myositis, rhabdomyolysis and acute kidney injury; (2) possible primary hyperparathyroidism (a low but detectable PTH); and (3) hypervitaminosis A. He was hydrated and given pamidronate, mycophenolate and prednisolone. Following initial biochemical and clinical improvement, he had multiple subsequent admissions for hypercalcaemia and renal deterioration. He continued taking GH and T despite counselling but died suddenly of a myocardial infarction. LEARNING POINTS: The differential diagnosis of hypercalcaemia is sometimes a challenge. Diagnosis may require multidisciplinary expertise and multiple and invasive investigations. There may be several disparate causes for hypercalcaemia, although one usually predominates. Maintaining ‘body image’ even with the use of harmful drugs may be an overpowering emotion despite counselling about their dangers. Bioscientifica Ltd 2020-07-05 /pmc/articles/PMC7354728/ /pubmed/32698126 http://dx.doi.org/10.1530/EDM-20-0032 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unique/Unexpected Symptoms or Presentations of a Disease
Ravindran, Ravikumar
Witczak, Justyna
Bahl, Suhani
Premawardhana, Lakdasa D K E
Adlan, Mohamed
Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title_full Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title_fullStr Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title_full_unstemmed Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title_short Myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
title_sort myositis, rhabdomyolysis and severe hypercalcaemia in a body builder
topic Unique/Unexpected Symptoms or Presentations of a Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354728/
https://www.ncbi.nlm.nih.gov/pubmed/32698126
http://dx.doi.org/10.1530/EDM-20-0032
work_keys_str_mv AT ravindranravikumar myositisrhabdomyolysisandseverehypercalcaemiainabodybuilder
AT witczakjustyna myositisrhabdomyolysisandseverehypercalcaemiainabodybuilder
AT bahlsuhani myositisrhabdomyolysisandseverehypercalcaemiainabodybuilder
AT premawardhanalakdasadke myositisrhabdomyolysisandseverehypercalcaemiainabodybuilder
AT adlanmohamed myositisrhabdomyolysisandseverehypercalcaemiainabodybuilder